UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 2154-8
Program Prior Authorization/Medical Necessity
Medication Hemlibra® (emicizumab-kxwh)
P&T Approval Date 11/2018, 11/2019, 9/2020, 9/2021, 9/2022, 9/2023, 9/2024, 5/2025
Effective Date 7/1/2025
1. Background:
Hemlibra (emicizumab-kxwh) is a bispecific factor IXa- and factor X-directed antibody indicated
for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and
pediatric patients ages newborn and older with hemophilia A (congenital factor VIII deficiency)
with or without factor VIII inhibitors.
2. Coverage Criteriaa:
A. Hemophilia A With Inhibitors
1. Initial Authorization
a. Hemlibra will be approved based on all of the following criteria
(1) Diagnosis of hemophilia A
-AND-
(2) Patient has developed high-titer factor VIII inhibitors ( > 5 Bethesda units [BU])
-AND-
(3) Prescribed for the prevention of bleeding episodes (i.e., routine prophylaxis)
Authorization of therapy will be issued for 12 months.
2. Reauthorization
a. Documentation of positive clinical response to Hemlibra therapy
Authorization will be issued for 12 months.
B. Hemophilia A Without Inhibitors
1. Initial Authorization
a. Hemlibra will be approved based on both of the following criteria
(1) One of the following:
© 2025 UnitedHealthcare Services Inc.
1
(a) Both of the following:
i. Diagnosis of severe hemophilia A
-AND-
ii. Documentation of endogenous factor VIII levels less than 1% of normal
factor VIII (< 0.01 IU/mL)
-OR-
(b) Both of the following:
i. One of the following
1. Both of the following
a. Diagnosis of moderate hemophilia A
-AND-
b. Documentation of endogenous factor VIII level >1% < 5% (greater
than or equal to 0.01 IU/mL to less than 0.05 IU/mL)
-OR-
2. Both of the following
a. Diagnosis of mild hemophilia A
-AND-
b. Documentation of endogenous factor VIII level > 5% (greater than
or equal to 0.05 IU/mL)
-AND-
ii. Submission of medical records (e.g., chart notes, laboratory values)
documenting a failure to meet clinical goals (e.g., continuation of
spontaneous bleeds, inability to achieve appropriate trough level, previous
history of inhibitors) after a trial of prophylactic factor VIII replacement
products
-OR-
(c) All of the following:
i. Patient is currently on Hemlibra therapy
-AND-
© 2025 UnitedHealthcare Services Inc.
2
ii. Diagnosis of hemophilia A
-AND-
iii. Patient has not received a manufacturer supplied sample at no cost in
prescriber office, or any form of assistance from the Genentech Patient
Foundation or the Genentech sponsored Hemlibra Co-pay Card program
(e.g., sample card which can be redeemed at a pharmacy for a free supply
of medication) as a means to establish as a current user of Hemlibra*
-AND-
(2) Hemlibra is prescribed for the prevention of bleeding episodes (i.e., routine
prophylaxis)
* Patients requesting initial authorization who were established on therapy via the receipt of a
manufacturer supplied sample at no cost in the prescriber’s office or any form of assistance from
the Genentech Patient Foundation or the Genentech Hemlibra Co-pay Card program shall be
required to meet initial authorization criteria as if patient were new to therapy.
Authorization of therapy will be issued for 12 months.
2. Reauthorization
a. Hemlibra will be approved based on the following criterion:
(1) Documentation of positive clinical response to Hemlibra therapy
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
4. References:
1. Hemlibra® [package insert]. South San Francisco, CA: Genentech, Inc., January 2024.
2. Oldenburg, J, Mahlangu JN, Kim, B, et al. Emicizumab Prophylaxis in Hemophilia A with
Inhibitors. N Engl J Med 2017; 377:809-818.
3. Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab Prophylaxis in Patients Who Have
Hemophilia A without Inhibitors. N Engl J Med. 2018;379:811-22.
© 2025 UnitedHealthcare Services Inc.
3
4. Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van Den Berg HM, Srivastava A, for the
Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders. Definitions in
hemophilia: communication from the SSC of the ISTH. J Thromb Haemost 2014;12:1935–9.
5. MASAC Recommendation on the Use and Management of Emicizumab-kxwh (Hemlibra®) for
Hemophilia A with and without Inhibitors. MASAC Document #268, April 27, 2022.
Program Prior Authorization/Medical Necessity - Hemlibra (emicizumab-kxwh)
Change Control
11/2018 New program
11/2019 Annual review. No changes to clinical coverage criteria. Updated
reference.
9/2020 Annual review. No changes to clinical coverage criteria.
9/2021 Annual review. No changes to clinical coverage criteria. Updated
reference.
9/2022 Annual review. Updated name of Genentech Access to Care Foundation
to Genentech Patient Foundation with no change to clinical intent.
Updated references.
9/2023 Annual review. Modified physician attestation to prescriber attestation.
Updated references.
9/2024 Annual review. Updated list of examples of extended half-life factor
VIII replacement products. Updated references.
5/2025 Removed criteria that patient is not to receive extended half-life factor
VIII replacement products for the treatment of breakthrough bleeding
episodes.
© 2025 UnitedHealthcare Services Inc.
4